EGFR and head and neck squamous cell carcinoma: Although advances in therapy based on a better understanding of HNSCC pathogenesis, as the association of Cetuximab (anti EGFR monoclonal antibody) to standard chemotherapy, treatments remain, at date, not very effective and only 40–50% of HNSCC patients will survive 5 years after the diagnosis [15, 16].